Oral-B Encourages Consumers to Brush up on Their Oral Care Regimen and Recognise Its Importance to Overall Body Health
Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact chronic periodontal diseases have on wider systemic disease.
The brand is leading the way in innovation, technology and research to help protect oral health and educate about the important connection between oral and overall body health. As part of the year-long partnership, Oral-B and Scientific American Custom Media are releasing a series of content, including educational resources from leading medical and dental researchers that will help readers better understand the connections between oral health and whole body health.
Oral diseases are at crisis level as it is estimated that they affect nearly 3.5 billion people worldwidei and in the midst of a global health pandemic, it is more crucial than ever to safeguard not only your oral health but your whole-body health too.
Jeremy A. Abbate, VP & Publisher at Scientific American explains: “Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health. It’s proven that periodontitis increasingly poses a significant risk to the development and progression of multiple systemic conditions and gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”
While warning signs can be as small as bleeding gums or even tooth loss, they can lead to more severe conditions such as heightened pregnancy complications, cognitive loss, poor diabetes control, and increases the risk of cardiovascular disease.
SYSTEMIC SPREAD OF PLAQUE BACTERIA THROUGHOUT THE BODY
A healthy mouth has minimal plaque build-up, ensuring oral bacteria cannot multiply, cause cavities, gum deterioration or spread beyond the mouth. However, when plaque build-up is present around the gum line and between teeth, it shelters oral bacteria (including P.gingivalis) from your toothbrush and natural defences. This provides the perfect conditions for the bacteria to thrive and cause inflammation-causing toxins that are known to spread throughout the rest of the body.
The formation of gum disease begins when plaque containing millions of bacteria coats the teeth, accumulates undisturbed. Acid produced by the bacteria can erode tooth enamel causing cavities and irritate the gums and cause gingivitis which can progress into periodontitis – a more serious infection that can lead to tooth loss.
When oral conditions worsen, the hidden plaque bacteria can cause an inflammatory response in the periodontal tissues that sets off a chain reaction, spreading systemically through the body via the circulatory system to other parts of the body. These oral bacteria are also found to be transmitted via the lungs and gastrointestinal tract.
DISEASES IMPACTED BY GUM DISEASE
- Stroke – Periodontitis may increase the risk for stroke. A continuous flow of bacteria into the bloodstream from exacerbated gum sites can trigger inflammation, prompting plaque growth and leading to blood clots.ii
- Diabetes - There is a two-way relationship between diabetes and periodontitis, with more severe periodontal tissue destruction observed in diabetic populations, due to poorly controlled glucose levels.iii iv
- Heart disease - Patients with periodontal disease are at increased risk for cardiovascular disease. Chronic gum inflammation may cause bad bacteria and toxins to enter the bloodstream and circulate to plaque sites in arterial walls.v
- Pregnancy gingivitis - Pregnant women are at increased risk of gingivitis and pregnant women with periodontitis are at increased risk for adverse pregnancy outcomes, including pre-term birth, low birth weight babies, and pregnancy hypertension (pre-eclampsia).vi
- Dementia - Patients with Alzheimer’s Disease and cognitive function loss have a higher risk for developing poor oral hygiene and periodontal disease. The relationship is bi-directional, as periodontal bacteria can also infect the brain and play a direct role in the build-up of amyloid brain lesions, leading to Alzheimer’s disease.vii
MAINTAINING A HEALTHY MOUTH AND BODY
Oral-B, the No.1 Dentist Recommended Toothbrush Brand Worldwide, is on a mission to make the invisible connection between oral health and whole-body wellness visible and to empower people to take their health into their own hands.
Following a daily holistic Oral-B regimen can help with maintaining a happy, healthy mouth:
-
Electric Toothbrush with a Round-Head
Oral-B brushes are round for a reason, to adapt to each individual tooth and reach between the teeth. The Oral-B iO’s revolutionary technology removes 100% more plaque than a manual brush to give you that professional clean feeling every single day.
-
Stannous Fluoride Toothpaste
Stannous Fluoride (SnF2) helps to protect your gums against bacterial plaque.
-
Mouth Rinse
Mouth rinses containing bioavailable Cetylpyridinium Chloride (CPC) formulated at 0.07% helps to reduce plaque.
-
Interdental Cleaning
Plaque easily accumulates and hides between teeth where toothbrushing can’t reach. Regular cleaning between teeth helps to remove plaque and helps protect gums.
-
Regular Oral-Health Check-Ups
Partner with your dental professional regularly to prevent and detect signs of gum infection at its earliest stages.
Scientific American educational resources developed in partnership with Oral B can be found here.
####
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by Dr. Robert Hutson, a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Artificial Intelligencery®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
i Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)
ii Janket SJ, Baird AE, Chuang SK, Jones JA. Meta- analysis of periodontal disease and risk for coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:559-569
iii Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998;3:51-61
iv Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: A two-way relationship. Diabetologia 2012;55:21-31.
v Blaizot A, Vergenes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: Meta-analyseis of observational studies. Int Dent J 2009; 59(4):197-209
vi Daalderop LD,Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF. Periodontal disease and pregnancy outcomes: Overview of systematic reviews. JDR Clinl Transl Res 2018;3:10-27. | Manrique-Corredor EJ, Orozco-Beltran D, Lopez-Pineda A, Quesada JA, Gil-Guillen VF, Carratala-Munuera C. Maternal periodontitis and preterm birth: systematic review and meta-analysis. Community Dent Oral Epidemiol 2019;47:243-251. | Chambrone L, Guglielmetti MR, Pannati CM, Chambrone LA. Evidence grade associating periodontitis to preterm birth and/or low birth weight: I. A systematic review of prospective cohort studies. J Clin Periodontol 2011;38:795-808. | Wei BJ, Chen YJ, Wu B. Periodontal disease and risk of preeclampsia: A meta- analysis of observational studies. PLOS ONE 2013;8:1-6. | Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol. 2008;Jan:7-22
vii Savitt ED, Socransky SS. Distribution of certain subgingival microbial species in selected periodontal conditions. J Periodontal Res 1984, 19 (2): 111-123.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005558/en/
Contact information
Oral-B press team
Jemma Western
oralb@publicisgroupe.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem10.6.2025 07:17:00 EEST | Press release
Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760138/en/ FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitaliza
China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor10.6.2025 07:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. “With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT
KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 04:00:00 EEST | Press release
Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e
IFF Appoints Virginia “Gina” Drosos to Board of Directors10.6.2025 00:46:00 EEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien
Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction9.6.2025 19:00:00 EEST | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/ Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park. The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two in Berlin, all of which are fully leased to hyperscale customers. The refinancing is part of Vantage’s wider
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom